Natus Medical Inc

Natus Medical, Inc. provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William New, Jr., Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natus Medical, Inc. engages in providing healthcare solutions. It also focuses on the diagnosis and treatment of central nervous and sensory system disorders. The company was founded by Maurizio Liverani, John Robert Camber Porter, William Jr. New, Brian Prinn and William W. Moore on May 26, 1987 and is headquartered in Middleton, WI.

MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock.

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

CareMax

Goldenstone Acquisition Ltd

US Well Services

NEW YORK , June 23, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: U.S. Well Services, Inc. (NASDAQ: USWS)'s sale to ProFrac Holding Corp. Under the terms of the merger agreement, USWS shareholders will receive 0.0561 shares of ProFrac Class A common stock for each share of USWS Class A common stock they own. If you are a USWS shareholder, click here to learn more about your rights and options.

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates USWS, GDST, NTUS, CMAX

NEW ORLEANS , June 6, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NATUS MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS

New York, New York--(Newsfile Corp. - June 6, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Natus Medical Inc. (NASDAQ: NTUS), relating to its proposed acquisition by ArchiMed. Under the terms of the...

The M&A Class Action Firm Reminds Investors of Its Investigation of Natus Medical Inc. - NTUS

New York, New York--(Newsfile Corp. - May 24, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Natus Medical Inc. (NASDAQ: NTUS), relating to its proposed acquisition by ArchiMed. Under the terms of the...

The M&A Class Action Firm Continues the Investigation of Natus Medical Inc. - NTUS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Natus Medical Incorporated (NasdaqGS: NTUS) to an affiliate of ArchiMed. Under the terms of the proposed transaction, shareholders of Natus will receive only $33.50 in cash for each share of Natus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,

NATUS MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Natus Medical Incorporated - NTUS

MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022.

Natus Medical Announces First Quarter 2022 Financial Results

Here is how Natus Medical (NTUS) and Option Care (OPCH) have performed compared to their sector so far this year.

Has Natus Medical (NTUS) Outpaced Other Medical Stocks This Year?

American Campus Communities

Flexible Solutions

Vidler Water Resouces

NEW YORK , April 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Campus Communities, Inc. (NYSE: ACC)'s sale to Blackstone related entities for $65.47 per share in cash. If you are an American Campus shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACC, NTUS, FSI, VWTR

Wilmington, Delaware--(Newsfile Corp. - April 19, 2022) - Rigrodsky Law, P.A. is investigating Natus Medical Inc. ("Natus") (NASDAQ: NTUS) regarding possible breaches of fiduciary duties and other violations of law related to Natus' agreement to be acquired by ArchiMed Group. Under the terms of the agreement, Natus' shareholders will receive $33.50 in cash for each share of Natus common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-natus-medical-inc.To contact Seth D....

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Natus Medical Inc. Buyout

Natus Medical Incorporated (NASDAQ: NTUS) shares are up 25% after the medical device solutions provider for screening, diagnosing and treating disorders that affect the brain sensory nervous systems ad neural pathways signed definitive agreement  to be bought by ArchiMed affiliate for $1.2 billion. Shareholders to receive 33.5 per share Stockholders will get $33.50 in cash for […] The post Here is why Natus Medical is up 25% appeared first on Invezz.

Here is why Natus Medical is up 25%

A suitor wants to take the company private.

Why Natus Medical Stock Surged Today

NEW YORK, April 18, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Natus Medical Incorporated ("Natus" or the "Company") (NASDAQ: NTUS), in connection with the proposed acquisition of the Company by an affiliate of ArchiMed. Under the terms of the merger agreement, the Company's shareholders will receive $33.50 in cash for each share of Natus common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Natus Medical Incorporated

MILWAUKEE , April 18, 2022 /PRNewswire/ -- Ademi LLP is investigating Natus (NASDAQ:NTUS) for possible breaches of fiduciary duty and other violations of law in its transaction with ArchiMed.  Click here to learn how to join the action: https://www.ademilaw.com/case/natus-medical-incorporated or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Wisconsin firm Ademi LLP investigates whether Natus Medical Incorporated has obtained a Fair Price in its transaction with ArchiMed

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Natus Medical Incorporated (NASDAQ: NTUS) to an affiliate of ArchiMed for $33.50 in cash per share is fair to Natus Medical shareholders. Halper Sadeh encourages Natus Medical shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation con

NTUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Natus Medical Incorporated Is Fair to Shareholders

Natus Medical is being acquired by ArchiMed for a 29% premium.

Natus Medical Soars. It's Being Taken Private by ArchiMed for $1.2 Billion.

Natus Medical Inc (NASDAQ: NTUS) will be acquired by ArchiMed, an investment firm focused exclusively on the healthcare industry, for approximately $1.2 billion.  Natus shareholders will receive $33.50 in cash for each share, representing a 29% premium to the closing price of the.

Neurodiagnostic Focused Natus Medical Goes Private In $1.2B Deal

Natus Medical Inc. NTUS, +0.58% announced Monday a deal to be acquired in a deal valued at $1.2 billion by an affiliate of investment firm ArchiMed. Natus Medical's stock was still halted for news until 7:30 a.m.

Natus Medical to be acquired at a 29% premium by ArchiMed

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash

PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions.

Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th

Is Natus Medical (NATUS) a great pick from the value investor's perspective right now? Read on to know more.

Is Natus Medical (NTUS) a Worthy Stock for Value Investors?

Natus Medical (NTUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Natus Medical (NTUS) Rating Upgrade to Buy

Natus Medical Incorporated (NTUS) CEO Thomas Sullivan on Q4 2021 Results - Earnings Call Transcript

Natus Medical (NTUS) delivered earnings and revenue surprises of 6.82% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Beats Q4 Earnings and Revenue Estimates

PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021.

News for Natus Medical Inc Stock (NTUS)